loading
Titan Pharmaceuticals Inc De stock is traded at $3.56, with a volume of 44,266. It is up +2.74% in the last 24 hours and down -11.33% over the past month. Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
See More
Previous Close:
$3.465
Open:
$3.46
24h Volume:
44,266
Relative Volume:
2.33
Market Cap:
$3.29M
Revenue:
$61,000
Net Income/Loss:
$-6.17M
P/E Ratio:
-6.2456
EPS:
-0.57
Net Cash Flow:
$-6.43M
1W Performance:
+10.22%
1M Performance:
-11.33%
6M Performance:
-41.83%
1Y Performance:
-34.10%
1-Day Range:
Value
$3.12
$3.79
1-Week Range:
Value
$3.12
$3.79
52-Week Range:
Value
$3.12
$14.80

Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile

Name
Name
Titan Pharmaceuticals Inc De
Name
Phone
(650) 244-4990
Name
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
Employee
4
Name
Twitter
@titanpharma
Name
Next Earnings Date
2024-06-28
Name
Latest SEC Filings
Name
TTNP's Discussions on Twitter

Compare TTNP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
3.56 3.29M 61,000 -6.17M -6.43M -8.20
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
409.03 105.21B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
713.55 78.48B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
633.51 37.55B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.62 31.19B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.85 27.43B 3.30B -501.07M 1.03B -2.1146

Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-26-19 Initiated Maxim Group Buy
Nov-10-17 Downgrade ROTH Capital Buy → Neutral

Titan Pharmaceuticals Inc De Stock (TTNP) Latest News

pulisher
Dec 16, 2024

KalVista Pharmaceuticals Taps Former AVEO Oncology Executive as New COO in Strategic Leadership Move - StockTitan

Dec 16, 2024
pulisher
Dec 11, 2024

Hepion Pharmaceuticals Terminates Strategic Merger with Pharma Two BMajor Deal Cancelled - StockTitan

Dec 11, 2024
pulisher
Dec 10, 2024

MIRA Pharmaceuticals' Novel Ketamine Drug Aces Preclinical Safety Tests, Phase I Trials Set for 2025 - StockTitan

Dec 10, 2024
pulisher
Dec 09, 2024

Universe Pharmaceuticals Announces $15M Direct Offering with Warrants; Univest Securities Leading Placement - StockTitan

Dec 09, 2024
pulisher
Dec 06, 2024

Fresh Tracks Therapeutics Faces Dissolution as Court Schedules Critical Delaware Hearing | FRTX Stock News - StockTitan

Dec 06, 2024
pulisher
Dec 04, 2024

KalVista Pharmaceuticals Awards Inducement Stock Options to New Executive Team Members - StockTitan

Dec 04, 2024
pulisher
Dec 03, 2024

Heron Therapeutics Wins Major Patent Battle Over CINVANTI, Blocks Generic Until 2035 - StockTitan

Dec 03, 2024
pulisher
Dec 03, 2024

X4 Pharmaceuticals Issues Major Stock Option Awards to New Employees at $0.371 Per Share - StockTitan

Dec 03, 2024
pulisher
Dec 02, 2024

VSee Health CEO Reveals AI Platform's 1.5M Monthly Telehealth Encounters on Bloomberg TV - StockTitan

Dec 02, 2024
pulisher
Dec 02, 2024

Terns Pharmaceuticals Grants 150,000 Share Options to New Employee at $6.24 - StockTitan

Dec 02, 2024
pulisher
Nov 27, 2024

Titan Pharmaceuticals faces Nasdaq compliance issues - Investing.com

Nov 27, 2024
pulisher
Nov 27, 2024

Titan Pharmaceuticals Faces Double Nasdaq Compliance Challenge Over Filing, Audit Issues | TTNP Stock News - StockTitan

Nov 27, 2024
pulisher
Nov 22, 2024

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan

Nov 22, 2024
pulisher
Nov 22, 2024

Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista - StockTitan

Nov 22, 2024
pulisher
Nov 21, 2024

Conduit Pharma Secures Key Patent for Autoimmune Drug AZD1656 in Major Japan Market | CDT Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 20, 2024

Lexicon Pharmaceuticals Appoints Former Eisai CEO Ivan Cheung to Board of Directors | LXRX Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 20, 2024

Melt Pharma's MELT-300 Shows Breakthrough Results in Phase 3 Sedation Trial | HROW Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 19, 2024

Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 19, 2024

Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 19, 2024

Conduit Pharmaceuticals Strengthens Board with 30-Year Investment Banking Veteran Simon Fry - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

NeuroBo Pharma Rebrands as MetaVia, Advances $70M Cardiometabolic Pipeline | NRBO Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Virpax Pharmaceuticals Raises $5M to Advance Pain Management Drug Development | VRPX Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 14, 2024

Elite Pharmaceuticals Revenue Surges 33% to $18.9M, Operating Profit Jumps 84% | ELTP Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

TFF Pharmaceuticals Announces Complete Shutdown, Appoints Wind-Down Specialist as CEO | TFFP Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Universe Pharmaceuticals Announces 15:1 Reverse Stock Split Amid NASDAQ Concerns | UPC Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Citius Phase 1 Trial Shows 27% Response Rate with LYMPHIR-Keytruda Combo in Cancer Study - StockTitan

Nov 11, 2024
pulisher
Nov 08, 2024

InMed Announces 1-for-20 Reverse Split to Maintain Nasdaq Listing - StockTitan

Nov 08, 2024
pulisher
Nov 07, 2024

NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Bionoid Pharma Unveils 5-Year AI-Powered Growth Strategy, Targets 15% EBITDA | BINP Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Acadia Pharma Sells FDA Priority Review Voucher for $150M, Boosts R&D Pipeline - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline - StockTitan

Nov 04, 2024

Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$69.84
price down icon 0.22%
$19.48
price up icon 2.29%
$40.30
price up icon 0.05%
$364.45
price up icon 1.00%
$184.05
price up icon 1.18%
$113.85
price down icon 0.16%
Cap:     |  Volume (24h):